Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Investment analysts at William Blair upped their Q1 2025 earnings per share (EPS) estimates for shares of Upstream Bio in a report issued on Wednesday, March 12th. William Blair analyst M. Phipps now expects that the company will post earnings of ($0.35) per share for the quarter, up from their prior estimate of ($0.40). The consensus estimate for Upstream Bio's current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio's Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($1.91) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.36) EPS, FY2028 earnings at ($1.53) EPS and FY2029 earnings at ($1.75) EPS.
Upstream Bio Trading Down 8.4 %
Shares of NASDAQ UPB traded down $0.83 during trading on Friday, reaching $9.04. The stock had a trading volume of 135,964 shares, compared to its average volume of 326,399. Upstream Bio has a one year low of $6.65 and a one year high of $29.46. The stock has a 50 day simple moving average of $9.62.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new position in Upstream Bio during the 4th quarter worth $25,000. US Bancorp DE bought a new position in Upstream Bio during the 4th quarter worth $27,000. Legal & General Group Plc bought a new position in Upstream Bio during the 4th quarter worth $28,000. Summit Investment Advisors Inc. bought a new position in Upstream Bio during the 4th quarter worth $30,000. Finally, Tower Research Capital LLC TRC bought a new position in Upstream Bio during the 4th quarter worth $47,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
See Also
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
